About
Palladio Biosciences develops lixivaptan, a drug in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a chronic condition characterized by numerous fluid-filled cysts in the kidneys.
Explore Palladio Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.